Back

Tensive secures up to €20 million EIB loan for REGENERA development

Verifying
  • Tensive signed a convertible loan agreement with the EIB for REGENERA development and commercialization.
  • €20 million will be provided in €8 million and €12 million tranches, each maturing after 20 years.
  • Tensive reported 12-month pivotal-trial data from all 94 enrolled patients on July 28, 2026.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.